|
Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer Clinical Trials Data presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, calls or treatment using a genuine doctor. We are not docs. Always consult your dr. on Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer conditions. Clinical Trials Search.org is a site dedicated to listing clinical research studies in human subjects. Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer Clinical research trials and Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer healthcare trials occur in a lot of of places throughout the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the potency of new drugs. The intent of the studies / undertakings is to figure out certain human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector corporations to locate remedies for all kinds of circumstances, including Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer. Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer Clinical Trials and other clinical trials allow volunteers to obtain health treatment alternatives before they are available to the masses. Many times the participants undergo treatment for free, and sometimes they are paid for their time. Occasionally there is a cost for a Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer clinical trial. Participants typically obtain the most effective healthcare available for their Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer condition. Dangers are a reality, nonetheless, and can include extra or frequent mD trips, medical hazards (potentially life-endangering), and/or the treatment being uneffective. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer  Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer
Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer
For Condition: Breast Cancer,Breast Neoplasms,Colorectal Neoplasms,Colon Cancer,Rectal Cancer,Colorectal Carcinoma,Colorectal Cancer
Status: No longer recruiting
Sponsor(s): Immunomedics, Inc. ,
Synopsis: The purpose of this trial is to determine the safety of hMN14 at different dose levels in the treatment of either colorectal or breast cancer.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Dose Comparison, Single Group Assignment, Safety Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Disease Characteristics: - Histologic or cytologic diagnosis or either, colonic, rectal, or breast carcinoma - Measurable lesion diagnosed by CT scan - Recurrent/metastatic disease considered surgically unresectable. Prior/Concurrent Therapy: - Chemotherapy: Patients who either have failed at least one regimen of standard systemic therapy, or are clinically asymptomatic and are not presently being considered for chemotherapy (Enrollment must occur at least 4 weeks beyond last treatment) - Other: Prior treatment with investigational agents is excluded unless follow-up is completed and patient is off study Patient Characteristics/Inclusion Criteria: - Performance Status: Patients with a Karnofsky performance status > 70% (or equivalent, ECOG 0-1) and expected survival of at least 3 months. - Hematopoietic: WBC >/= 3000 mm3, neutrophils >/= 1500 mm3, platelets >/= 75,000, CEA < 300 ng/mL - Hepatic: Serum bilirubin /= 40% by required MUGA/2D-ECHO study. - Pulmonary: Patients with FEV1 >/= 60% by required Pulmonary Function Tests - Other: Patients agreeing to use a medically effective method of contraception during and for a period of 3 months after the treatment period. A pregnancy test will be preformed on each premenopausal female of childbearing potential immediately prior to entry into the study. Patients able to understand and give written informed consent. Patients with a significant concurrent medical condition that could affect the patient's ability to tolerate or complete the study.
Total Enrollment: 30
Location and Contact Information:
Overall Study Official:
TerenceRugg, Study Director, Immunomedics, Inc.
Hoag Cancer Center
Newport Beach, California, 92658
United States
Additional Information:
Study ID Numbers: IM-T-hMN14-04;
Study Start Date: February 2000
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00041652
Other Rectal Cancer Studies:
1. Computed Tomographic Colonography in Detecting Colorectal Polyps or Cancer
2. Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer
3. Phase I Study of SU006668 in Patients With Advanced Solid Tumors
4. Erlotinib and Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Colorectal Cancer
5. Biological Therapy in Treating Patients With Metastatic Cancer
Related Studies:
Other Rectal Cancer Clinical Trials
Other California Clinical Trials
Other Newport Beach Clinical Trials
Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer
|
|
|
|
|
|
|
|
